Full data from Alnylam's pivotal givosiran programme show a big impact for severe patients, though a case still needs to be made for a broader population.
Yesterday’s high-profile presentation of the Regenerate trial failed to quash concerns about Ocaliva in Nash, despite Intercept’s best attempts to polish the data.
The IPO hopeful Cirius Therapeutics presented intriguing Nash data at EASL, but with the final readout from a phase IIb study looming the company’s real value is hard to…
Today’s deal will see the companies take a triple combination into clinical trials.
A look at the abstract on Intercept’s Regenerate trial seems to confirm the earlier topline result, ahead of a full data presentation later today.
Encouraging results from Viking Therapeutics’ lead Nash project have prompted the company to ask how low it can go.
Encouraging early data from an academic trial of Clovis's Rubraca raise hopes that Parps could emerge as a more tolerable maintenance therapy for some pancreatic…
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.